| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/18/2011 | CA2581945C Hexafluoroisopropanol substituted ether derivatives |
| 01/18/2011 | CA2573219C Hepatitis c inhibitor dipeptide analogs |
| 01/18/2011 | CA2568590C Propane-1,3-dione derivative or salt thereof useful as gnrh receptor antagonist |
| 01/18/2011 | CA2566160C Pyrrolopyrimidine derivatives useful in cancer treatment |
| 01/18/2011 | CA2564201C Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands |
| 01/18/2011 | CA2561303C Gossypol co-crystals and the use thereof |
| 01/18/2011 | CA2557671C Treatment and prophylaxis of sepsis and septic shock |
| 01/18/2011 | CA2557395C Benzopyran compound |
| 01/18/2011 | CA2555295C Extended release coated mini-tablets of venlafaxine hydrochloride |
| 01/18/2011 | CA2511984C Indazolamides with analgesic activity |
| 01/18/2011 | CA2511301C Acylsufonamide compounds as inhibitors of rna-dependent rna viral polymerase |
| 01/18/2011 | CA2503274C Basic medicine-containing preparation |
| 01/18/2011 | CA2500225C Pyrazole compounds |
| 01/18/2011 | CA2493310C 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition |
| 01/18/2011 | CA2491895C Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/18/2011 | CA2481876C Inhalation kit comprising inhalable powder of tiotropium |
| 01/18/2011 | CA2477773C A stable diclofenac-tromethamine composition for the topical treatment of oropharyngeal cavity disorders |
| 01/18/2011 | CA2477769C Ophthalmic composition comprising ascomycin |
| 01/18/2011 | CA2475630C N-acyl-phosphatidyl-ethanolamines and/or mixtures of n-acyl-ethanolamines with phosphatidic acids or lysophosphatidic acids |
| 01/18/2011 | CA2462374C Substituted 4-phenyl-4-(1h-imidazol-2-yl)-piperidine derivatives for reducing ischaemic damage |
| 01/18/2011 | CA2458797C Preparation and diabetic use of gibeberellins |
| 01/18/2011 | CA2455145C Pregnancy-related serine protease |
| 01/18/2011 | CA2452386C Granulates containing liposoluble substances and a process for the preparation thereof |
| 01/18/2011 | CA2451504C A process for the isolation of a major harmful oxidant from cigarette smoke |
| 01/18/2011 | CA2441964C New pharmaceutical compositions based on anticholinergics and endothelin antagonists |
| 01/18/2011 | CA2440472C Methods of treating acne |
| 01/18/2011 | CA2436825C Process for the crystallization of (r)- or (s)-lansoprazole |
| 01/18/2011 | CA2432148C Tri-heterocyclic compounds and a pharmaceutical comprising them as an active ingredient |
| 01/18/2011 | CA2432077C Tetrahydro-(benzo or thieno)-azepine-pyrazine and triazine derivatives as mglur 1 antagonists |
| 01/18/2011 | CA2416874C 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 01/18/2011 | CA2414670C Anthelminthic agents for the prevention of parasitic infections in humans and animals |
| 01/18/2011 | CA2401089C Anaesthetic formulations |
| 01/18/2011 | CA2384502C Use of .alpha.-linolenic acid metabolites for treatment or prevention of cancer |
| 01/18/2011 | CA2384134C N-arylmethylthioanilide compounds useful for the inhibition of the replication of hiv |
| 01/18/2011 | CA2383737C Muc-1 derived peptides |
| 01/18/2011 | CA2372850C Synergistic combination comprising roflumilast and a pde-3 inhibitor |
| 01/18/2011 | CA2368637C Topical treatment or prevention of ocular infections |
| 01/18/2011 | CA2331460C Heterocyclic inhibitors of p38 |
| 01/18/2011 | CA2328073C Methods and compositions using cetirizine in combination with leukotriene inhibitors for treating conditions responsive to leukotriene inhibition |
| 01/18/2011 | CA2326579C Systems, methods and computer program products for guiding the selection of therapeutic treatment regimens |
| 01/18/2011 | CA2321881C Non-imidazole alkylamines as histamine h3-receptor ligands and their therapeutic applications |
| 01/18/2011 | CA2320807C Method and composition for treatment of inflammatory conditions |
| 01/18/2011 | CA2311125C Apoptosis inhibitor |
| 01/18/2011 | CA2310534C Methods and compositions for treating primary and secondary tumors of the central nervous system (cns) |
| 01/18/2011 | CA2284399C Use of magnesium (mg2+) for the preparation of a therapeutic composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 01/18/2011 | CA2269895C Use of ginkgo biloba flavonoidic extract substantially devoid or terpenes for oral hygiene and composition containing such extract |
| 01/18/2011 | CA2260858C Polynucleotide vaccine formulation against pathologies of the horse |
| 01/18/2011 | CA2260266C Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors |
| 01/18/2011 | CA2189055C Methods for modulating t cell responses by manipulating intracellular signal transduction |
| 01/16/2011 | CA2685842A1 A method for the treatment of cancer |
| 01/14/2011 | CA2709589A1 Civamide patch for localized post-incisional neuropathic pain |
| 01/13/2011 | WO2011006169A1 Methods for diagnosis and treatment of thrombotic disorders mediated by cyp2c19*2 |
| 01/13/2011 | WO2011006158A2 Targeting nad biosynthesis in bacterial pathogens |
| 01/13/2011 | WO2011006157A2 Rxr agonist compounds and methods |
| 01/13/2011 | WO2011006144A1 Methods of treating and preventing neurological disorders using docosahexaenoic acid |
| 01/13/2011 | WO2011006143A2 Compounds and compositions for the treatment of parasitic diseases |
| 01/13/2011 | WO2011006100A1 Method of wound healing and scar modulation |
| 01/13/2011 | WO2011006097A2 Methods For Treating Toxicity |
| 01/13/2011 | WO2011006079A2 Ophthalmic formulations of reversed liquid crystalline phase materials and methods of using |
| 01/13/2011 | WO2011006074A1 SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
| 01/13/2011 | WO2011006070A2 Genetic association of polymorphisms in perilipin (plin) gene with resistance to weight loss |
| 01/13/2011 | WO2011006066A1 Cb receptor agonists |
| 01/13/2011 | WO2011006061A1 Diyne compositions |
| 01/13/2011 | WO2011006040A2 Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases |
| 01/13/2011 | WO2011006012A1 Pharmaceutical compositions |
| 01/13/2011 | WO2011006007A1 Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor |
| 01/13/2011 | WO2011006000A1 Berberine derivatives useful for modulating lipid levels and their methods of synthesis |
| 01/13/2011 | WO2011005969A2 Etomidate analogues that do not inhibit adrenocortical steroid synthesis |
| 01/13/2011 | WO2011005929A1 Piperidine derivative and its use for the treatment of diabets and obesity |
| 01/13/2011 | WO2011005907A1 Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis |
| 01/13/2011 | WO2011005886A1 Method of reducing multi-drug resistance using inositol tripyrophosphate |
| 01/13/2011 | WO2011005871A1 Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists |
| 01/13/2011 | WO2011005864A2 Ethyleneoxide butyleneoxide block copolymer compositions |
| 01/13/2011 | WO2011005853A2 Compositions and methods of topical drug delivery for the treatment of carpal tunnel syndrome |
| 01/13/2011 | WO2011005842A1 Anti-rsv compounds |
| 01/13/2011 | WO2011005832A1 Stable crystalline polymorphs of the dipotassium salt of (s) -2- {4- [2- (2, 4-diamin0-quinaz0lin-6-yl) -ethyl] -benzoylamino} -4-methylenξ-penta nedioic acid |
| 01/13/2011 | WO2011005811A1 Combination therapy for the treatment of diabetes |
| 01/13/2011 | WO2011005790A1 Compositions and methods for inhibition of cancers |
| 01/13/2011 | WO2011005761A1 Novel nucleic acid prodrugs and methods use thereof |
| 01/13/2011 | WO2011005759A2 Lonidamine analogues for fertility management |
| 01/13/2011 | WO2011005714A2 Bendamustine liposomal compositions |
| 01/13/2011 | WO2011005688A1 Hdac 6 inhibitor-based methods for treating cancer |
| 01/13/2011 | WO2011005681A1 Inhibiting inflammation with milk oligosaccharides |
| 01/13/2011 | WO2011005674A1 Dual-acting pyrazole antihypertensive agents |
| 01/13/2011 | WO2011005671A1 Methods of treating pdnv and ponv with extended release ondansetron compositions |
| 01/13/2011 | WO2011005660A1 Tofa analogs useful in treating dermatological disorders or conditions |
| 01/13/2011 | WO2011005645A1 Polymorph of [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)pyrimidin-5-yl] |
| 01/13/2011 | WO2011005636A1 Tetrahydronapthyridine orexin receptor antagonists |
| 01/13/2011 | WO2011005609A2 Imaging gastrointestinal volumes and motility |
| 01/13/2011 | WO2011005595A2 2-5a analogs and their methods of use |
| 01/13/2011 | WO2011005593A2 Schistosomiasis vaccine compositions and methods of use |
| 01/13/2011 | WO2011005574A2 Compositions and methods for regulating chondrocyte proliferation in bone disorders |
| 01/13/2011 | WO2011005520A1 Deuterium-modified triazolo-pyridazine derivatives as gaba-a receptor modulators |
| 01/13/2011 | WO2011005515A2 Bis-trifluoromethyl honokiol analogs and their use in treating cancers |
| 01/13/2011 | WO2011005473A2 Methods for treating or preventing fatigue |
| 01/13/2011 | WO2011005355A1 Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria |
| 01/13/2011 | WO2011005354A2 Gallium formulation for the treatment and prevention of infectious diseases |
| 01/13/2011 | WO2011005330A1 Compounds, compositions, and methods for preventing metastasis of cancer cells |
| 01/13/2011 | WO2011005295A1 Modulators of the sphingosine-1-phosphate (s1p) receptor useful for the treatment of disorders related thereto |
| 01/13/2011 | WO2011005290A1 Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |